Analysis of SARS-CoV-2 Delta variant transmissibility across New England, USA

NewsGuard 100/100 Score

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant of concern became globally dominant shortly following its emergence in India in early 2021, owing to greater transmissibility compared to other variants.

Numerous reports have demonstrated the enhanced transmissibility of the Delta variant from the aspect of both epidemiological studies, with genomic surveillance revealing the spread of Delta through communities, as well as by in vitro analytical methods, where the spike protein of this variant bears enhanced affinity towards the human angiotensin-converting enzyme 2 (ACE2) receptor.

Study: Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA. Image Credit: RUKSUTAKARN studio / Shutterstock.com

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

However, transmissibility varies between populations based on innate demographics and vaccine adoption rates. To this end, a recent study published on the preprint server medRxiv* compares the transmissibility of the SARS-CoV-2 Alpha and Delta variants in six states across New England in the United States, finding variation in epidemiological dynamics based on community behavior.

About the study

In the current study, the researchers partnered with community genomics surveillance programs in Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont. These programs provided reverse-transcriptase qualitative polymerase chain reaction (RT-qPCR) data collected over the course of the pandemic, along with the rate of new cases discovered of each variant in each location.

Each state was noted to experience a similar change in variant frequency over time, with the Alpha variant becoming dominant in April 2021 and rapidly replaced by the Delta variant in June 2021. While a number of other minor SARS-CoV-2 variants constituted a large portion of total SARS-CoV-2 infections during the time that the Alpha variant was dominant, the Delta variant represented between 94-100% of all cases by the final week of 2021 and had become more widely dominant geographically.

Delta variant transmissibility

To compare the transmissibility of the Alpha and Delta variants, the group narrowed the time under examination to within 90 days following the first emergence of each variant. Interestingly, the Alpha variant at first appears to outpace the Delta variant during the early stages of outbreak, though the authors suggest that lacking surveillance data at this time caused an overestimation in transmissibility.

In total, the Delta variant was estimated to be 163% more transmissible than the Alpha variant in Vermont, 151% in Connecticut, 98% in Rhode Island, 95% in Maine, 75% in New Hampshire, and 37% in Massachusetts. The U.K. has reported an estimated 40-80% enhanced transmissibility for the Delta variant based on epidemiological data, and differences in population density, vaccine uptake, non-pharmaceutical interventions, and the presence of competing variants drive the variation observed.   

On average, the Delta variant became dominant in each location within 71 days, representing a range of 54-92 days across New England. No association between relative emergence speed and infections per capita was noted.

Given the genetic similarity of the Delta variant across New England, the difference observed in transmissibility is likely due to population-based differences. An association between vaccination rates and Delta variant emergence speed was found, with the variant taking longer to become dominant where vaccine adoption was high.

The timing of the Alpha and Delta variant outbreaks may have influenced the observed rate of Delta variant dominance. This is because, at the time of the Alpha variant outbreak, none of the population was yet vaccinated, while between 18-37% of the population was vaccinated by April.

As vaccination rates increased across New England, non-pharmaceutical measures such as lockdowns and travel restrictions were relaxed prior to the arrival of the Delta variant. Thus, these factors may have potentially caused the appearance of higher transmissibility.

Enhanced viral loads

RT-qPCR data with known SARS-CoV-2 variant origin were compared. As previously reported previously, the Delta variant was associated with a higher viral load than the Alpha or other variants.

This held true, even when accounting for the possibility of declining viral load in samples collected from individuals without recent infections and across different testing methods. Thus, the large viral load of the Delta variant may be the primary reason for its enhanced transmissibility.

Conclusion

While the complete mechanism behind the observed difference in Delta variant transmissibility between locations has yet to be elucidated, this study has demonstrated that factors such as the implementation and adherence to non-pharmaceutical measures and vaccine uptake strongly influence the dynamics of SARS-CoV-2 infections and outbreaks.

The authors suggest that, given the global dominance of the Delta variant, the next globally dominant strain to replace it is likely to emerge from the B.1.617.2 clade, to which the delta variant it belongs. However, it cannot be predicted when or where this variant will emerge, thus highlighting the importance of continued genomic surveillance.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:

Article Revisions

  • Apr 29 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Michael Greenwood

Written by

Michael Greenwood

Michael graduated from the University of Salford with a Ph.D. in Biochemistry in 2023, and has keen research interests towards nanotechnology and its application to biological systems. Michael has written on a wide range of science communication and news topics within the life sciences and related fields since 2019, and engages extensively with current developments in journal publications.  

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Greenwood, Michael. (2023, April 29). Analysis of SARS-CoV-2 Delta variant transmissibility across New England, USA. News-Medical. Retrieved on April 18, 2024 from https://www.news-medical.net/news/20211011/Analysis-of-SARS-CoV-2-Delta-variant-transmissibility-across-New-England-USA.aspx.

  • MLA

    Greenwood, Michael. "Analysis of SARS-CoV-2 Delta variant transmissibility across New England, USA". News-Medical. 18 April 2024. <https://www.news-medical.net/news/20211011/Analysis-of-SARS-CoV-2-Delta-variant-transmissibility-across-New-England-USA.aspx>.

  • Chicago

    Greenwood, Michael. "Analysis of SARS-CoV-2 Delta variant transmissibility across New England, USA". News-Medical. https://www.news-medical.net/news/20211011/Analysis-of-SARS-CoV-2-Delta-variant-transmissibility-across-New-England-USA.aspx. (accessed April 18, 2024).

  • Harvard

    Greenwood, Michael. 2023. Analysis of SARS-CoV-2 Delta variant transmissibility across New England, USA. News-Medical, viewed 18 April 2024, https://www.news-medical.net/news/20211011/Analysis-of-SARS-CoV-2-Delta-variant-transmissibility-across-New-England-USA.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Annual COVID-19 vaccine proves to be a wise investment for personal health and pocketbook